Raynaud's phenomenon: a modern view of the problem
DOI:
https://doi.org/10.15574/SP.2024.8(144).107114Keywords:
Raynaud's phenomenon, epidemiology, risk factors for development, clinic, diagnosis, childrenAbstract
Raynaud's phenomenon (RP) is present in almost all patients with systemic connective tissue diseases and is often the first clinical manifestation of the disease, preceding skin and organ involvement several years later.
Aim - to study and analyze available data regarding the prevalence, risk factors for development, clinical features and diagnosis of RF based on an analysis of modern literature data.
Raynaud's phenomenon is quite common in the general population (about 5%), and is usually caused by cold exposure or significant changes in temperature (primary RF). There are primary and secondary RF. In both primary and secondary RF, the typical episode is characterized by the sudden appearance of cold fingers (or toes) coupled with sharply limited changes in skin color (white) due to restricted blood flow, followed by cyanotic skin color (blue), indicating on tissue hypoxia. During rewarming, the ischemic phase (white or blue attack) usually lasts 15-20 minutes. After recovery, the skin turns red, which leads to reperfusion erythema. To establish a diagnosis, blue-white changes are usually necessary. In patients with highly pigmented skin, skin changes may be more visible on the palmar surface of the fingers.
Conclusions. Despite the significant prevalence of RF, it is extremely difficult to establish its exact prevalence, especially in the pediatric population. If RF is suspected, the doctors should pay attention not only to changes in the color of the extremities, but also to swelling and telangiectasia in the patient during examination and medical history. Despite the absence of a “gold standard” for diagnosing RF, nail fold capillaroscopy is recognized as the main method for diagnosing RF today.
The authors declare that there is no conflict of interest.
References
Abdulle AE, Arends S, van Goor H, Brouwer E, van Roon AM, Westra J et al. (2021). Low body weight and involuntary weight loss are associated with Raynaud's phenomenon in both men and women. Scand J Rheumatol. 50(2): 153-160. https://doi.org/10.1080/03009742.2020.1780310; PMid:33063580
Breen ID, Brumfiel CM, Patel MH, Butterfield RJ, VanderPluym JH, Griffing L et al. (2021). Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon. JAMA Netw Open. 4(4): e217934. https://doi.org/10.1001/jamanetworkopen.2021.7934; PMid:33871613 PMCid:PMC8056280
Chatterjee S. (2023). Coexistence of erythromelalgia and Raynaud's phenomenon. Joint Bone Spine. 90(4): 105561. https://doi.org/10.1016/j.jbspin.2023.105561; PMid:36933784
Choi E, Henkin S.(2021). Raynaud's phenomenon and related vasospastic disorders. Vasc Med. 26(1): 56-70. https://doi.org/10.1177/1358863X20983455; PMid:33566754
Cutolo M, Smith V. (2021). Detection of microvascular changes in systemic sclerosis and other rheumatic diseases. Nat Rev Rheumatol. 17(11): 665-677. https://doi.org/10.1038/s41584-021-00685-0; PMid:34561652
Cutolo M, Smith V, Furst DE, Khanna D, Herrick AL. (2017). Points to consider-Raynaud's phenomenon in systemic sclerosis. Rheumatology (Oxford). 56(5): 45-48. https://doi.org/10.1093/rheumatology/kex199; PMid:28992170 PMCid:PMC5850109
Cutolo M, Vanhaecke A, Ruaro B, Deschepper E, Ickinger C, Melsens K et al. (2018). EULAR Study Group on Microcirculation in Rheumatic Diseases. Is laser speckle contrast analysis (LASCA) the new kid on the block in systemic sclerosis? A systematic literature review and pilot study to evaluate reliability of LASCA to measure peripheral blood perfusion in scleroderma patients. Autoimmun Rev. 17(8): 775-780. https://doi.org/10.1016/j.autrev.2018.01.023; PMid:29885540
Goldman RD. (2019). Raynaud phenomenon in children. Can Fam Physician. 65(4): 264-265.
Haque A, Hughes M. (2020). Raynaud's phenomenon. Clin Med (Lond). 20(6): 580-587. https://doi.org/10.7861/clinmed.2020-0754; PMid:33199324 PMCid:PMC7687329
Herrick AL, Wigley FM. (2020). Raynaud's phenomenon. Best Pract Res Clin Rheumatol. 34(1): 101474. https://doi.org/10.1016/j.berh.2019.101474; PMid:32007400
Hughes M, Herrick AL. (2016). Raynaud's phenomenon. Best Pract Res Clin Rheumatol. 30(1): 112-32. https://doi.org/10.1016/j.berh.2016.04.001; PMid:27421220
Hughes M, Huang S, Pauling JD, Sabbagh M, Khanna D. (2022). The clinical relevance of Raynaud's phenomenon symptom characteristics in systemic sclerosis. Clin Rheumatol. 41(10): 3049-3054. https://doi.org/10.1007/s10067-022-06206-y; PMid:35583625
Jones GT, Herrick AL, Woodham SE, Baildam EM, Macfarlane GJ, Silman AJ. (2003). Occurrence of Raynaud's phenomenon in children ages 12-15 years: prevalence and association with other common symptoms. Arthritis Rheum. 48(12): 3518-3521. https://doi.org/10.1002/art.11340; PMid:14674003
Jud P, Raggam RB, Hafner F. (2020). Paraneoplastic acral vascular syndrome. CMAJ. 192(46): E1470. https://doi.org/10.1503/cmaj.200430; PMid:33199454 PMCid:PMC7682999
Khouri C, Blaise S, Carpentier P, Villier C, Cracowski JL, Roustit M. (2016). Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers. Br J Clin Pharmacol. 82(1): 6-16. https://doi.org/10.1111/bcp.12912; PMid:26949933 PMCid:PMC4917788
Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G et al. (2008). Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 58(12): 3902-3912. https://doi.org/10.1002/art.24038; PMid:19035499
Mansueto N, Rotondo C, Corrado A, Cantatore FP. (2021). Nailfold capillaroscopy: a comprehensive review on common findings and clinical usefulness in non-rheumatic disease. J Med Invest. 68(1.2): 6-14. https://doi.org/10.2152/jmi.68.6; PMid:33994482
Marushko KYu, Marushko TV. (2018). Raynaud's syndrome in children. Children's doctor. 1: 27-34.
Maverakis E, Patel F, Kronenberg DG, Chung L, Fiorentino D, Allanore Y et al. (2014). International consensus criteria for the diagnosis of Raynaud's phenomenon. J Autoimmun. 48-49: 60-65. https://doi.org/10.1016/j.jaut.2014.01.020; PMid:24491823 PMCid:PMC4018202
Nawaz I, Nawaz Y, Nawaz E, Manan MR, Mahmood A. (2022). Raynaud's Phenomenon: Reviewing the Pathophysiology and Management Strategies. Cureus. 14(1): e21681. https://doi.org/10.7759/cureus.21681
Nigrovic PA, Fuhlbrigge RC, Sundel RP. (2003). Raynaud's phenomenon in children: a retrospective review of 123 patients. Pediatrics. 111(4 Pt 1): 715-721. https://doi.org/10.1542/peds.111.4.715; PMid:12671102
Pain CE, Constantin T, Toplak N, Moll M, Iking-Konert C, Piotto DP et al. (2016). Paediatric Rheumatology European Society (PRES) Juvenile Scleroderma Working Group. Raynaud's syndrome in children: systematic review and development of recommendations for assessment and monitoring. Clin Exp Rheumatol. 34; Suppl 100(5): 200-206.
Pavlov-Dolijanović S, Damjanov N, Ostojić P, Susić G, Stojanović R, Gacić D et al. (2006). The prognostic value of nailfold capillary changes for the development of connective tissue disease in children and adolescents with primary raynaud phenomenon: a follow-up study of 250 patients. Pediatr Dermatol. 23(5): 437-442. https://doi.org/10.1111/j.1525-1470.2006.00278.x; PMid:17014637
Pitarokoili K, Kreuter A, Gold R, Kleiter I. (2014). Severe Raynaud's phenomenon after treatment with interferon beta for multiple sclerosis. BMJ. 349: g6166. https://doi.org/10.1136/bmj.g6166
Prete M, Favoino E, Giacomelli R, Afeltra A, Cantatore FP, Bruno C et al. (2020). GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale). Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control study. Clin Exp Med. 20(1): 31-37. https://doi.org/10.1007/s10238-019-00589-0; PMid:31679095
Purdie G, Harrison A, Purdie D. (2009). Prevalence of Raynaud's phenomenon in the adult New Zealand population. N Z Med J. 122(1306): 55-62.
Rigante D, Fastiggi M, Ricci F, D'Errico F, Bracci B, Guerriero C. (2017). Handy Hints About Raynaud's Phenomenon in Children: A Critical Review. Pediatr Dermatol. 34(3): 235-239. https://doi.org/10.1111/pde.13129; PMid:28523890
Ruaro B, Bruni C, Wade B, Baratella E, Confalonieri P, Antonaglia C et al. (2021). Laser Speckle Contrast Analysis: Functional Evaluation of Microvascular Damage in Connective Tissue Diseases. Is There Evidence of Correlations With Organ Involvement, Such as Pulmonary Damage? Front Physiol. 12: 710298. https://doi.org/10.3389/fphys.2021.710298; PMid:34707506 PMCid:PMC8542764
Ruaro B, Smith V, Sulli A, Pizzorni C, Tardito S, Patané M et al. (2019). Innovations in the Assessment of Primary and Secondary Raynaud's Phenomenon. Front Pharmacol. 10: 360. https://doi.org/10.3389/fphar.2019.00360; PMid:31073287 PMCid:PMC6495407
Scolnik M, Vasta B, Hart DJ, Shipley JA, McHugh NJ, Pauling JD. (2016). Symptoms of Raynaud's phenomenon (RP) in fibromyalgia syndrome are similar to those reported in primary RP despite differences in objective assessment of digital microvascular function and morphology. Rheumatol Int. 36(10): 1371-1377. https://doi.org/10.1007/s00296-016-3483-6; PMid:27136918 PMCid:PMC5020104
Smith V, Herrick AL, Ingegnoli F, Damjanov N, De Angelis R, Denton CP et al. (2020). EULAR Study Group on Microcirculation in Rheumatic Diseases and the Scleroderma Clinical Trials Consortium Group on Capillaroscopy. Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. Autoimmun Rev. 19(3): 102458. https://doi.org/10.1016/j.autrev.2020.102458; PMid:31927087
Turan E, Kilic SS. (2019). Retrospective view of primary Raynaud's phenomenon in childhood. Reumatol Clin (Engl Ed). 15(6): e92-e95. https://doi.org/10.1016/j.reuma.2017.12.012; PMid:29426682
Uthman IW, Khamashta MA. (2006). Livedo racemosa: a striking dermatological sign for the antiphospholipid syndrome. J Rheumatol. 33(12): 2379-2382.
Wigley FM, Flavahan NA. (2016). Raynaud's Phenomenon. N Engl J Med. 375(6): 556-565. https://doi.org/10.1056/NEJMra1507638; PMid:27509103
Wigley FM, Herrick AL, Flavahan NA. (2024). Clinical manifestations and diagnosis of Raynaud phenomenon. In: UpToDate, Connor RF (Ed), Wolters Kluwer. (Accessed on Jul 17, 2023). https://doi.org/10.1007/978-3-031-52581-0
Wilkinson JD, Leggett SA, Marjanovic EJ, Moore TL, Allen J, Anderson ME et al. (2018). A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud's Phenomenon. Arthritis Rheumatol. 70(6): 903-911. https://doi.org/10.1002/art.40457; PMid:29457381 PMCid:PMC6001804
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Modern pediatrics. Ukraine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
